TherapeuticsMD, Inc. (TXMD) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
32/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseTXMD / S&P 9.41% / 15.20% |
WinTXMD / S&P 27.78% / 15.00% |
LoseTXMD / S&P -50.00% / 50.40% |
| 2026-Q12/3 |
WinTXMD / S&P 23.93% / -4.33% |
WinTXMD / S&P 82.13% / 11.30% |
LoseTXMD / S&P -111.11% / 27.70% |
| 2025-Q42/3 |
WinTXMD / S&P 50.93% / 2.65% |
WinTXMD / S&P 71.61% / 9.00% |
LoseTXMD / S&P -72.22% / 13.40% |
| 2025-Q31/3 |
LoseTXMD / S&P -6.90% / 8.12% |
WinTXMD / S&P 75.19% / 4.61% |
LoseTXMD / S&P -107.41% / 13.45% |
| 2025-Q22/3 |
WinTXMD / S&P 24.73% / 10.94% |
WinTXMD / S&P 156.93% / 4.83% |
LoseTXMD / S&P -92.59% / 10.63% |
| 2025-Q12/3 |
WinTXMD / S&P 8.14% / -4.27% |
WinTXMD / S&P 53.54% / 4.98% |
LoseTXMD / S&P -73.91% / 10.57% |
| 2024-Q41/3 |
LoseTXMD / S&P -48.19% / 2.41% |
WinTXMD / S&P 35.25% / 5.25% |
LoseTXMD / S&P -82.00% / 6.15% |
| 2024-Q30/3 |
LoseTXMD / S&P 3.11% / 5.89% |
LoseTXMD / S&P -97.70% / 5.89% |
LoseTXMD / S&P -103.77% / 6.11% |
| 2024-Q20/3 |
LoseTXMD / S&P -29.69% / 4.28% |
LoseTXMD / S&P -98.57% / 5.38% |
LoseTXMD / S&P -112.39% / 5.12% |
| 2024-Q10/3 |
LoseTXMD / S&P 1.78% / 10.56% |
LoseTXMD / S&P -98.28% / 5.71% |
LoseTXMD / S&P -103.96% / 5.59% |
| 2023-Q40/3 |
LoseTXMD / S&P -25.50% / 11.69% |
LoseTXMD / S&P -98.14% / 6.81% |
LoseTXMD / S&P -108.26% / 7.78% |
| 2023-Q30/3 |
LoseTXMD / S&P -26.70% / -3.27% |
LoseTXMD / S&P -207.87% / 7.52% |
LoseTXMD / S&P -831.63% / -5.03% |
| 2023-Q21/3 |
WinTXMD / S&P 9.87% / 8.74% |
LoseTXMD / S&P -277.76% / 9.50% |
LoseTXMD / S&P -225.65% / -8.57% |
| 2023-Q10/3 |
LoseTXMD / S&P -32.92% / 7.50% |
LoseTXMD / S&P -519.83% / 10.77% |
LoseTXMD / S&P -180.29% / -15.69% |
| 2022-Q41/3 |
LoseTXMD / S&P -15.81% / 7.56% |
WinTXMD / S&P 2619.12% / 11.88% |
LoseTXMD / S&P TXMD unavailable / -17.99% |
| 2022-Q30/3 |
LoseTXMD / S&P -33.27% / -4.88% |
LoseTXMD / S&P -170.78% / 13.47% |
LoseTXMD / S&P TXMD unavailable / -1.41% |
| 2022-Q20/3 |
LoseTXMD / S&P -47.63% / -16.10% |
LoseTXMD / S&P -146.29% / 13.71% |
LoseTXMD / S&P TXMD unavailable / 11.04% |
| 2022-Q11/3 |
WinTXMD / S&P 5.56% / -4.60% |
LoseTXMD / S&P -122.90% / 15.97% |
LoseTXMD / S&P TXMD unavailable / 42.23% |
| 2021-Q40/3 |
LoseTXMD / S&P -51.35% / 11.03% |
LoseTXMD / S&P -96.03% / 15.00% |
LoseTXMD / S&P TXMD unavailable / 96.40% |
| 2021-Q31/3 |
LoseTXMD / S&P -37.82% / 0.58% |
WinTXMD / S&P 56.11% / 10.77% |
LoseTXMD / S&P TXMD unavailable / 69.42% |
| 2021-Q21/3 |
LoseTXMD / S&P -11.19% / 8.55% |
WinTXMD / S&P 35.50% / 6.58% |
LoseTXMD / S&P TXMD unavailable / 51.81% |
| 2021-Q12/3 |
WinTXMD / S&P 10.74% / 6.17% |
WinTXMD / S&P 25.08% / -1.06% |
LoseTXMD / S&P TXMD unavailable / 7.39% |
| 2020-Q41/3 |
LoseTXMD / S&P -23.42% / 12.15% |
WinTXMD / S&P 30.67% / -3.72% |
LoseTXMD / S&P TXMD unavailable / -33.42% |
| 2020-Q32/3 |
WinTXMD / S&P 26.40% / 8.93% |
WinTXMD / S&P 49.85% / -2.04% |
LoseTXMD / S&P TXMD unavailable / -27.10% |
| 2020-Q21/3 |
LoseTXMD / S&P 17.92% / 20.54% |
WinTXMD / S&P 236.62% / -0.46% |
LoseTXMD / S&P TXMD unavailable / -27.11% |
| 2020-Q11/3 |
LoseTXMD / S&P -56.20% / -19.60% |
WinTXMD / S&P 256.13% / 3.47% |
LoseTXMD / S&P TXMD unavailable / -14.75% |
| 2019-Q41/3 |
LoseTXMD / S&P -33.33% / 9.07% |
WinTXMD / S&P 208.38% / 5.36% |
LoseTXMD / S&P TXMD unavailable / 2.99% |
| 2019-Q32/3 |
WinTXMD / S&P 39.62% / 1.70% |
WinTXMD / S&P 156.60% / 5.02% |
LoseTXMD / S&P TXMD unavailable / 0.21% |
| 2019-Q21/3 |
LoseTXMD / S&P -46.61% / 4.30% |
WinTXMD / S&P 15.61% / 6.64% |
LoseTXMD / S&P TXMD unavailable / 8.65% |
| 2019-Q11/3 |
WinTXMD / S&P 27.82% / 13.65% |
LoseTXMD / S&P -1.77% / 8.12% |
LoseTXMD / S&P TXMD unavailable / 14.29% |
| 2018-Q40/3 |
LoseTXMD / S&P -41.92% / -13.52% |
LoseTXMD / S&P -4.04% / 9.05% |
LoseTXMD / S&P TXMD unavailable / 18.23% |
| 2018-Q30/3 |
LoseTXMD / S&P 5.13% / 7.71% |
LoseTXMD / S&P -11.71% / 10.21% |
LoseTXMD / S&P TXMD unavailable / 19.06% |
| 2018-Q21/3 |
WinTXMD / S&P 28.13% / 3.43% |
LoseTXMD / S&P -11.94% / 9.03% |
LoseTXMD / S&P TXMD unavailable / 14.46% |
| 2018-Q10/3 |
LoseTXMD / S&P -19.37% / -0.76% |
LoseTXMD / S&P -10.03% / 7.68% |
LoseTXMD / S&P TXMD unavailable / 12.46% |
| 2017-Q41/3 |
WinTXMD / S&P 14.18% / 6.64% |
LoseTXMD / S&P -13.32% / 7.03% |
LoseTXMD / S&P TXMD unavailable / 13.82% |
| 2017-Q30/3 |
LoseTXMD / S&P 0.38% / 4.48% |
LoseTXMD / S&P -16.38% / 5.68% |
LoseTXMD / S&P TXMD unavailable / 17.57% |
| 2017-Q20/3 |
LoseTXMD / S&P -26.81% / 3.09% |
LoseTXMD / S&P -9.40% / 4.83% |
LoseTXMD / S&P TXMD unavailable / 17.74% |
| 2017-Q11/3 |
WinTXMD / S&P 24.78% / 6.07% |
LoseTXMD / S&P -10.61% / 3.67% |
LoseTXMD / S&P TXMD unavailable / 13.32% |
| 2016-Q40/3 |
LoseTXMD / S&P -15.27% / 3.82% |
LoseTXMD / S&P -3.90% / 2.09% |
LoseTXMD / S&P TXMD unavailable / 7.05% |
| 2016-Q31/3 |
LoseTXMD / S&P -19.88% / 3.85% |
WinTXMD / S&P 9.21% / 0.20% |
LoseTXMD / S&P TXMD unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | TXMD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 100.00% | 20.78% |
| Annualized return | 100.00% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | TXMD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -94.38% | 83.14% |
| Annualized return | -43.77% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | TXMD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.37% | 319.30% |
| Annualized return | -39.74% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |